Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Company Deals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Bristol-Myers Squibb Secures FDA Approval for Iberdomide Combination in Multiple Myeloma – First‑Ever Nod Based on MRD‑Negative Response Data

Fineline Cube Aug 17, 2026
Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Fineline Cube Aug 14, 2026
Company Deals

Shandong Boan Biotechnology Partners with HKUST for Biomedicine Innovation

Fineline Cube May 24, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) has entered into a partnership with the...

Company Deals

PacBio Appoints Haorui Gene as Official Distributor in China

Fineline Cube May 24, 2025

US-based sequencing solutions provider PacBio (NASDAQ: PACB) has appointed China’s Haorui Gene as an official...

Company Drug

Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A

Fineline Cube May 23, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received marketing approval...

Company Drug

CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study

Fineline Cube May 23, 2025

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that it has published an abstract of...

Company Deals

Viz.ai Partners with Sanofi and Regeneron to Deploy AI Solution for COPD

Fineline Cube May 23, 2025

US-based Viz.ai this week announced a multi-year partnership with France-based Sanofi (NASDAQ: SNY) and US-based...

Company Drug

GSK’s Nucala Receives FDA Approval for COPD Treatment

Fineline Cube May 23, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...

Company Drug

Merck’s Welireg Launched in China for Rare Genetic Disorder Treatment

Fineline Cube May 23, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the commercial launch of its hypoxia-inducible...

Company Drug

NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment

Fineline Cube May 23, 2025

China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...

Company Drug

Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025

Fineline Cube May 23, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing...

Company Deals

Meinian Onehealth Partners with Alibaba DAMO Academy for AI-Driven Disease Screening

Fineline Cube May 23, 2025

China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...

Company Deals

Lead Healthcare Raises RMB 100M in Angel Financing to Boost AI-Driven Life Science Instruments

Fineline Cube May 23, 2025

China-based Lead Healthcare Technology (Guangzhou) Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Deals

WinHealth Pharma Expands Long-Term Partnership with Merz Therapeutics

Fineline Cube May 23, 2025

China-based Hong Kong WinHealth Pharma Group this week formally entered into a long-term partnership with...

Company Deals

Servier Acquires BioNova’s BN104 for Acute Leukemia Treatment

Fineline Cube May 23, 2025

French pharmaceutical firm Servier announced a definitive agreement to acquire BN104 from BioNova Pharmaceuticals (Shanghai)...

Company Drug

ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC

Fineline Cube May 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) and its US partner Instil Bio Inc...

Company Drug Policy / Regulatory

UCB’s Keppra Procurement Resumed in Shanghai After Regulatory Halt

Fineline Cube May 23, 2025

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification resuming the procurement of UCB’s...

Company Deals

RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion

Fineline Cube May 23, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares...

Company Drug

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US

Fineline Cube May 23, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has received approval from the US...

Company Drug

Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC

Fineline Cube May 23, 2025

China-based Jacobio Pharma (HKG: 1167) announced that it has received marketing approval from the National...

Company

AstraZeneca Shuts Down Neuroscience Research Group to Focus on Core Areas

Fineline Cube May 23, 2025

AstraZeneca (AZ; NASDAQ: AZN) confirmed the closure of its neuroscience research group during its 2025...

Company Drug

Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes

Fineline Cube May 23, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing...

Posts pagination

1 … 199 200 201 … 708

Recent updates

  • Sino Medical Sciences Wins Turkish Approval for Ghunter Intracranial Thrombectomy Stent – Broadening Global Footprint in Ischemic Stroke Care
  • Bristol-Myers Squibb Secures FDA Approval for Iberdomide Combination in Multiple Myeloma – First‑Ever Nod Based on MRD‑Negative Response Data
  • Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development
  • CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included
  • ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Sino Medical Sciences Wins Turkish Approval for Ghunter Intracranial Thrombectomy Stent – Broadening Global Footprint in Ischemic Stroke Care

Company Drug

Bristol-Myers Squibb Secures FDA Approval for Iberdomide Combination in Multiple Myeloma – First‑Ever Nod Based on MRD‑Negative Response Data

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.